Neil DeSai, MD, MHS
Alejandro Berlin, MD, MSc
Open to Accrual
De-Intensification Study: To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with RT alone instead of 6 months ADT + RT experience non-inferior rate of distant metastasis.
Intensification Study: To determine whether men with NCCN UIRprostate cancer who are in the higher genomic risk (Decipher score ≥0.40) willhave a superior metastasis-free survival through treatment intensification withdarolutamide added to the standard of RT plus 6 months ADT.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.